Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice

Journal of Endocrinology

Volumn 210, Issue 1, 2011, Pages 37-46

  Schuyler, Corinne A ^a   Ta, Nga N ^b   Li, Yanchun ^b   Lopes Virella, Maria F ^a,b   Huang, Yan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GELATINASE B; GLUCOSE; INSULIN GLARGINE; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CYTOKINE RELEASE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOLIPOPROTEINS E; DIABETIC ANGIOPATHIES; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERGLYCEMIA; INSULIN; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; RANDOM ALLOCATION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUNICA INTIMA; U937 CELLS;

EID: 79960319152     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-10-0420     Document Type: Article

References (38)

1. Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D & Dandona P 2001 Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). Journal of Clinical Endocrinology and Metabolism 86 5988-5991.
2. Bai YL, Huang HC, Li JZ, Zhao YY & Wang HY 2005 High glucose regulates the production of MMP-9 in podocyte through ERK1/2 signal pathway. Zhonghua Yi Xue Za Zhi 85 1451-1455.
3. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F & Tiret L 2003 Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 1579-1585.
4. Brocheriou I, Maouche S, Durand H, Braunersreuther V, Le Naour G, Gratchev A, Koskas F, Mach F, Kzhyshkowska J & Ninio E 2011 Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 214 316-324.
5. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME & Jandeleit-Dahm KA 2004 Irbesartan but not amlodipine suppresses diabetesassociated atherosclerosis. Circulation 109 1536-1542.
6. Collins AR, MeehanWP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA & Law RE 2001 Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 21 365-371.
7. Falk E, Shah PK & Fuster V 1995 Coronary plaque disruption. Circulation 92 657-671.
8. Galis ZS & Khatri JJ 2002 Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circulation Research 90 251-262.
9. Galis ZS, Sukhova GK, Lark MW & Libby P 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation 94 2493-2503.
10. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V & Filetti S 2009 Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 32 1550-1552.
11. Gray JL & Shankar R 1995 Down regulation of CD11b and CD18 expression in atherosclerotic lesion-derived macrophages. American Surgeon 61 674-679 (discussion 679-680).
12. Gurjar MV, Sharma RV & Bhalla RC 1999 eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arteriosclerosis, Thrombosis, and Vascular Biology 19 2871-2877.
13. Hayek T, Hussein K, Aviram M, Coleman R, Keidar S, Pavoltzky E & Kaplan M 2005 Macrophage foam-cell formation in streptozotocininduced diabetic mice: stimulatory effect of glucose. Atherosclerosis 183 25-33.
14. Jarrett RJ 1981 Atherosclerosis, diabetes and obesity. Proceedings of the Nutrition Society 40 209-212.
15. Khan HA, Sobki SH & Khan SA 2007 Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clinical and Experimental Medicine 7 24-29.
16. Lee SJ, Bae SS, Kim KH, Lee WS, Rhim BY, Hong KW & Kim CD 2007 High glucose enhances MMP-2 production in adventitial fibroblasts via Akt1-dependent NF-kappaB pathway. FEBS Letters 581 4189-4194.
17. Lehr HA, Mankoff DA, Corwin D, Santeusanio G & Gown AM 1997 Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. Journal of Histochemistry and Cytochemistry 45 1559-1565.
18. Li Y, Samuvel DJ, Sundararaj KP, Lopes-Virella MF & Huang Y 2010 IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. Journal of Cellular Biochemistry 110 248-259.
19. Libby P 1995 Molecular bases of the acute coronary syndromes. Circulation 91 2844-2850.
20. Libby P & Theroux P 2005 Pathophysiology of coronary artery disease. Circulation 111 3481-3488.
21. Liu CP, Yeh JL, Wu BN, Chai CY, Chen IJ & Lai WT 2011 KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance. British Journal of Pharmacology 162 126-135.
22. Loftus IM, Naylor AR, Bell PR & Thompson MM 2001 Plasma MMP-9 - a marker of carotid plaque instability. European Journal of Vascular and Endovascular Surgery 21 17-21.
23. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V & Koenig W 2003 Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 23 283-288.
24. McKellar GE, McCarey DW, Sattar N & McInnes IB 2009 Role for TNF in atherosclerosis? Lessons from autoimmune disease Nature Reviews. Cardiology 6 410-417.
25. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M & Alvarez-Sabin J 2003 Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107 598-603.
26. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V & Fallon JT 2000 Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 2180-2184.
27. Nakashima Y, Plump AS, Raines EW, Breslow JL & Ross R 1994 ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arteriosclerosis and Thrombosis 14 133-140.
28. Nareika A, Sundararaj KP, Im YB, Game BA, Lopes-Virella MF & Huang Y 2009 High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis 202 363-371.
29. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P & Zinman B 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 353 2643-2653.
30. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D & Schmidt AM 1998 Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4 1025-1031.
31. Richardson PD, Davies MJ & Born GV 1989 Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2 941-944.
32. Soedamah-Muthu SS & Stehouwer CD 2005 Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus: management strategies. Treatments in ndocrinology 4 75-86.
33. Sundstrom C & Nilsson K 1976 Establishment and characterization of a human histiocytic lymphoma cell line (U-937). International Journal of Cancer 17 565-577.
34. Tang Y & Li GD 2004 Chronic exposure to high glucose impairs bradykininstimulated nitric oxide production by interfering with the phospholipase-C-implicated signalling pathway in endothelial cells: evidence for the involvement of protein kinase C. Diabetologia 47 2093-2104.
35. Tse J, Martin-McNaulty B, Halks-Miller M, Kauser K, DelVecchio V, Vergona R, Sullivan ME & Rubanyi GM 1999 Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol. Atherosclerosis 144 303-313.
36. Verhoeven BA, Moll FL, Koekkoek JA, van der Wal AC, de Kleijn DP, de Vries JP, Verheijen JH, Velema E, Busser E, Schoneveld A et al. 2006 Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 37 2054-2060.
37. Yadav A, Saini V & Arora S 2010 MCP-1: chemoattractant with a role beyond immunity: a review. Clinica Chimica Acta 411 1570-1579.
38. Yakubenko VP, Belevych N, Mishchuk D, Schurin A, Lam SC & Ugarova TP 2008 The role of integrin alpha D beta2 (CD11d/CD18) in monocyte/macrophage migration. Experimental Cell Research 314 2569-2578.